The optimal performance of this LC-MS/MS method has been confirmed through its application in a multicenter, double-blind, placebo-controlled, phase II clinical trial, investigating the therapeutic potential of ambroxol as a disease-modifying agent for GBA1-PD. The gene discussed is GBA1; the disease is Parkinson disease.